BofA Lifts Elevance Health Target to $480 Before Q3 Report
BofA Securities raised its ELV price target above analyst consensus, citing confidence in long-term earnings growth despite near-term cost pressures.
Bank of America Securities has nudged its price target for Elevance Health (ELV) higher — from $460 to $480 per share — positioning the call ahead of the managed-care giant's third-quarter earnings release. The revised target sits meaningfully above the broader analyst consensus of roughly $451, signaling that BofA's analysts see more upside than the Street currently prices in.
The upgrade comes against a complicated backdrop. Elevance posted mixed second-quarter results earlier this year, with elevated medical-cost ratios weighing on profitability — a headwind that has bedeviled much of the managed-care sector as post-pandemic utilization patterns remain stubbornly high. Yet BofA appears willing to look through that near-term turbulence, betting that the company's underlying earnings power will reassert itself.
Read more One Year After Bitcoin's $19B Shock: What Crypto Actually Learned →
Central to that thesis is Elevance's own forward guidance. The company has reaffirmed its adjusted earnings outlook for fiscal 2026 and projected at least 12% earnings growth in fiscal 2027 — a trajectory that, if achieved, would represent a meaningful acceleration from current levels. That kind of multi-year visibility is relatively rare in an industry where medical-cost inflation can shift quarterly, and it likely provides BofA with a tangible anchor for its above-consensus target.
For investors weighing managed-care exposure, the divergence between BofA's target and the analyst consensus is itself instructive. It suggests the market remains divided on how quickly Elevance can normalize its cost structure and whether its government and commercial membership trends can sustain premium growth. The Q3 report will be a critical data point in resolving that debate.
Continue reading at AD HOC NEWS.
